Mechanisms and emerging strategies for irinotecan-induced diarrhea

• Published in: European journal of pharmacology Vol. 974; p. 176614
• Main Authors: Xu, Shengkun, Lan, Huiyin, Huang, Chengyi, Ge, Xingnan, Zhu, Ji
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 05.07.2024
• Subjects: Biomarker; Chemotherapy; Colorectal cancer; Irinotecan-induced diarrhea; UGT1A1; Chemotherapy; Biomarker; UGT1A1; Colorectal cancer; Irinotecan-induced diarrhea
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2024.176614

Irinotecan (also known as CPT-11) is a topoisomerase I inhibitor first approved for clinical use as an anticancer agent in 1996. Over the past more than two decades, it has been widely used for combination regimens to treat various malignancies, especially in gastrointestinal and lung cancers. However, severe dose-limiting toxicities, especially gastrointestinal toxicity such as late-onset diarrhea, were frequently observed in irinotecan-based therapy, thus largely limiting the clinical application of this agent. Current knowledge regarding the pathogenesis of irinotecan-induced diarrhea is characterized by the complicated metabolism of irinotecan to its active metabolite SN-38 and inactive metabolite SN-38G. A series of enzymes and transporters were involved in these metabolic processes, including UGT1A1 and CYP3A4. Genetic polymorphisms of these metabolizing enzymes were significantly associated with the occurrence of irinotecan-induced diarrhea. Recent discoveries and progress made on the detailed mechanisms enable the identification of potential biomarkers for predicting diarrhea and as such guiding the proper patient selection with a better range of tolerant dosages. In this review, we introduce the metabolic process of irinotecan and describe the pathogenic mechanisms underlying irinotecan-induced diarrhea. Based on the mechanisms, we further outline the potential biomarkers for predicting the severity of diarrhea. Finally, based on the current experimental evidence in preclinical and clinical studies, we discuss and prospect the current and emerging strategies for the prevention of irinotecan-induced diarrhea.